British drug major AstraZeneca Plc. (AZN.L,AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the Boston-based company at $39 billion.
The deal comes amid AstraZeneca is in late-stage development of a COVID-19 vaccine in partnership with the University of Oxford.
The cash and ADS consideration represents an 45% premium to Alexion shareholders based on the closing stock price of Alexion on 11 December 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.